Remote ischemic preconditioning (RIPC; repeated short reversible periods of ischemia) protects the heart against subsequent ischemic injury. We explored whether RIPC can attenuate post-exercise changes in cardiac troponin T (cTnT) and cardiac function in healthy individuals. In a randomized, crossover design, 14 participants completed 1-h cycling time trials (TT) on two separate visits; preceded by RIPC (arms/legs, 4 3 5-min 220 mmHg), or SHAM-RIPC (20 mmHg). Venous blood was sampled before and 0-, 1-, and 3-h post-exercise to assess high sensitivity (hs-) cTnT and brain natriuretic peptide (NT-proBNP). Echocardiograms were performed at the same time points to assess left and right ventricular systolic (ejection fraction; EF and right ventricular fractional area change; RVFAC, respectively) and diastolic (early transmitral flow velocities; E) function. Baseline hs-cTnT was not different between RIPC and SHAM. Post-exercise hscTnT levels were consistently lower following RIPC (18 AE 3 vs 21 AE 3; 19 AE 3 vs 23 AE 3; and 20 AE 2 vs 25 AE 2 ng/L at 0, 1 and 3-h post-exercise, respectively; P < 0.05). There was no main effect of time, trial, or interaction for NT-proBNP and left ventricular EF or RVFAC (all P < 0.05). A main effect of time was evident for E which transiently declined immediately after exercise to a similar level in both trials (0.85 AE 0.04 vs 0.74 AE 0.04 m/s, respectively; P < 0.05). In summary, RIPC was associated with lower hs-cTnT levels after exercise but there was no independent effect of RIPC for NT-proBNP or LV systolic and diastolic function. The lower hs-cTnT levels after RIPC suggests that further research should evaluate the role of ischemia in exercise-induced elevation in hs-cTnT.
Remote ischemic preconditioning (RIPC; repeated short reversible periods of ischemia) protects the heart against subsequent ischemic injury. We explored whether RIPC can attenuate post-exercise changes in cardiac troponin T (cTnT) and cardiac function in healthy individuals. In a randomized, crossover design, 14 participants completed 1-h cycling time trials (TT) on two separate visits; preceded by RIPC (arms/legs, 4 3 5-min 220 mmHg), or SHAM-RIPC (20 mmHg). Venous blood was sampled before and 0-, 1-, and 3-h post-exercise to assess high sensitivity (hs-) cTnT and brain natriuretic peptide (NT-proBNP). Echocardiograms were performed at the same time points to assess left and right ventricular systolic (ejection fraction; EF and right ventricular fractional area change; RVFAC, respectively) and diastolic (early transmitral flow velocities; E) function. Baseline hs-cTnT was not different between RIPC and SHAM. Post-exercise hscTnT levels were consistently lower following RIPC (18 AE 3 vs 21 AE 3; 19 AE 3 vs 23 AE 3; and 20 AE 2 vs 25 AE 2 ng/L at 0, 1 and 3-h post-exercise, respectively; P < 0.05). There was no main effect of time, trial, or interaction for NT-proBNP and left ventricular EF or RVFAC (all P < 0.05). A main effect of time was evident for E which transiently declined immediately after exercise to a similar level in both trials (0.85 AE 0.04 vs 0.74 AE 0.04 m/s, respectively; P < 0.05). In summary, RIPC was associated with lower hs-cTnT levels after exercise but there was no independent effect of RIPC for NT-proBNP or LV systolic and diastolic function. The lower hs-cTnT levels after RIPC suggests that further research should evaluate the role of ischemia in exercise-induced elevation in hs-cTnT.
Several previous studies have demonstrated the presence of elevated serum levels of cardiac troponin (cTn), a biomarker of cardiomyocyte damage, during and after an exercise bout . Furthermore, strenuous exercise can lead to an acute, transient decrease in both systolic and diastolic cardiac function (Oxborough et al., 2011; Scott et al., 2009) . While studies reporting cTn-elevation or a decline in cardiac function have typically employed prolonged, strenuous exercise (e.g., marathon, triathlon) (Douglas et al., 1990; Neilan et al., 2006) , comparable findings have been reported after short duration exercise (~1 h) (Duttaroy et al., 2012; Tjora et al., 2011) . It has been speculated, but never tested, that acute changes in cTn and cardiac function after exercise may be related to the presence of local, subclinical ischemia during strenuous exercise (Ellison et al., 2012) . Alternative (non-ischemia) explanations must also be considered to explain post-exercise elevations in cTn, such as mechanical stress, the atherosclerotic burden, and/or the presence of myocardial fibrosis (M€ ohlenkamp et al., 2008 , 2014 Breuckmann et al., 2009) .
Ischemic preconditioning (IPC) refers to the exposure of an organ (e.g., the heart) to repeated short bouts of ischemia and was introduced in 1986 as an effective intervention to attenuate cardiac damage after subsequent prolonged ischemia in animals (Murry et al., 1986) . Interestingly, the protective effects of IPC on the heart are also present when IPC is applied to remote areas, such as the limbs, and is commonly referred to as remote IPC (RIPC). Studies in humans have demonstrated that RIPC reduces cardiac damage in response to acute ischemic events and cardiac surgery (Cheung et al., 2006; Hausenloy et al., 2007; Hong et al., 2012; Loukogeorgakis et al., 2007; Heusch et al., 2015) , although conflicting results have been published (Hausenloy et al., 2015; Meybohm et al., 2015) . RIPC, therefore, provides a method capable of attenuating ischemia-induced damage in the myocardium. Despite this a single previous study from El Messaoudi et al. (2013) found that RIPC did not alter exercise-induced cardiac troponin 1 (cTnI) in healthy volunteers. Important limitations in that study were the relatively mild exercise stimulus and RIPC exposure as well as a lack of insight into cardiac function.
Consequently, the present study extended previous work and tested the hypothesis that exercise-related changes in cTn, NT-proBNP, and cardiac function can be attenuated when 1-h strenuous cycle exercise is preceded by RIPC and therefore may relate to ischemia to the heart during strenuous exercise.
Methods Participants
Fourteen healthy, recreationally trained to well-trained cyclists (age, 29 AE 8; body mass, 71.6 AE 11.5 kg; height, 179 AE 9 cm; BMI 22.4 AE 1.6) were recruited. Participants were undertaking regular endurance training (>3 aerobic exercise sessions per week). We excluded subjects with any illness or injury who had the potential to impact the 1-h cycling time trial (TT) performance. Participants who had any personal or early family history of cardiovascular disease were excluded from participating in the study. This study was approved by the local Ethics Committee and all participants provided informed consent after reading participant information sheets and were fully familiarized to all testing procedures.
Experimental design
In a single blind, randomized crossover design study, participants undertook three exercise sessions within the physiology laboratories at Liverpool John Moores University involving a maximal cycling test and two TTs. On the first laboratory visit, a maximal incremental cycling test to volitional exhaustion was completed in order to assess peak oxygen uptake and classify participant training status. The graded cycling test was completed at least 7 days before the first experimental TT. Visits 2 and 3 involved the completion of a 1-h cycling TT (maximum distance achieved in 1 h) protocol preceded by RIPC or SHAM. TTs were separated by a minimum of 7 days. Data Collection of blood samples and echocardiography was performed before and after (0, 1, and 3 h) the TT. All tests were completed at the same time of day to minimize the impact of circadian variation on exercise performance and outcome parameters (Atkinson & Reilly, 1996) . Participants were asked to attend the lab in a euhydrated state and to have abstained from intense exercise, caffeine, and alcohol intake for a minimum of 24 h before the exercise.
Experimental protocols
Visit 1 (maximal cycle test)
The graded maximal cycle test was completed on a cycle ergometer (Lode; Excalibur sport VS, Groningen, The Netherlands). The exercise test was preceded by a warm-up of 5 min at 50 W. The incremental test began at a workload of 50 W and increased by 25 W per min until volitional exhaustion was achieved. Oxygen consumption was continually assessed using an automated online gas analysis system (Oxycon; COSMED, Rome, Italy). Heart rate was measured continuously using short-range telemetry (Polar Electro Oy, Finland). Achievement of VO 2max was deemed when two of the three following criteria was met: (a) A plateau in VO 2 despite a continual increase in cycling power output; (b) A heart rate (HR) within 10 beats of age predicted maximum; (c) A respiratory exchange ratio of above 1.10 (Howley et al., 1995) .
Remote ischemic preconditioning (RIPC) and SHAM
Before TT commencement, RIPC or SHAM was performed in the supine position using bilateral arterial occlusion on both the arms and legs (alternating between left and right). Automated pressure cuffs (Hokanson, Washington, DC, USA) were placed proximally around the (left or right) upper arms and thighs. Pressure cuffs were unilaterally inflated to 220 mmHg (RIPC) or 20 mmHg (SHAM) on ipsilateral upper and lower limbs. Limb occlusion lasted for 5 min to block arterial inflow and was interspersed with 5 min of reperfusion. As the pressure cuffs were deflated, the blood pressure cuffs on the opposite side of the body and were inflated on both limbs for 5 min. This process was repeated 4 times (40 min total IPC time).
Visits 2 and 3 Exercise Protocol
Immediately after the RIPC or SHAM procedure, participants completed a maximal 1-h cycling TT using a computerized cycling program (Racer Mate CompuTrainer, Seattle, USA). Participants used their own bikes where possible to improve consistency between both road-and lab-cycling positions during experimental trials. Rate of perceived exertion (RPE) was monitored every 10 min using the Borg scale (Borg, 1982) . HR was measured throughout exercise using short-range telemetry and average power output (W) was recorded from the CompuTrainer software. Participants were made aware of time and HR throughout the TT, but were blinded to all other physiological feedback until the completion of the final TT. Pre-and immediately post-exercise, body mass was recorded using an electronic weighing scale (SECA, Hamburg, Germany) along with heart rate, systolic, and diastolic blood pressure using an automated sphygmomanometer (Dinamap; GE Medical, Milwaukee, Wisconsin, USA). Biomarkers and cardiac function were assessed over four time points: pre (PRE); immediately post (POST-OH); 1-h post (POST-1H), and 3-h post (POST-3H) TT exercise.
Measurements
Biomarkers Serum cardiac troponin T (cTnT) and NT-proBNP were assessed from whole blood sampled by repetitive venipuncture. In total, four blood samples of 5 mL were taken per trial. Whole blood was spun down, pipetted and serum was stored at À80°C. All serum samples were analyzed in a single session.
Cardiac troponin
The Roche diagnostics high-sensitivity cardiac troponin T (hs-cTnT) assay was used. The hs-cTnT measurements were performed using an Elecsys Cobas E-unit (Roche Diagnostics, Haywards Heath, UK). The detection limit of the assay is 3 ng/L with an upper limit of 10000 ng/L. The claimed 10% coefficient of variation (CV) is 13 ng/L with a 99th centile of 14 ng/L of a healthy reference population.
N terminal pro B-type natriuretic peptide
NT-proBNP was measured by a solid phase, two-site chemiluminescent sandwich immunoassay using an Immulite 2500 (Siemens Healthcare Diagnostics, Frimley, UK). The detection limit of the assay was 20 ng/L with a measuring range up to 35000 ng/L. The interassay % CV was 5.0 to 4.0% in the range 40.9 to 32096 ng/L.
Cardiac function
Cardiac function was examined using trans-thoracic echocardiography. Scans were performed by a trained sonographer using standardized protocols (Mor-Avi et al., 2011) . All images were collected with the participant lying in the left lateral decubitus position. Acquisition and analysis were performed using VividQ and EchoPac (GE Medical, Horton, Norway). During scans, all settings were optimized to obtain maximum signal-to-noise ratio. Key images and outcome measures were as follows. From a parasternal long-axis view, M-mode scans characterized left ventricle (LV) dimension at end-diastole (LVED) and at end-systole (LVES). Apical twoand four-chamber views allowed the examination of LV enddiastolic (LVEDV) and end-systolic (LVESV) volumes using the Simpson Biplane method. This facilitated the estimation of ejection fraction (EF). Right ventricular (RV) size and dimension were measured at end-diastole from the outflow tract using a parasternal long-axis view and at the inflow from an apical four-chamber orientation. RV end-diastolic area and end-systolic area were calculated by tracing around the endocardium from a modified apical four-chamber orientation and RV fractional area change (RVFAC) was calculated. LV diastolic filling was assessed using pulsed-wave Doppler echocardiographic recordings from the apical four-chamber view. Specifically, spectral Doppler envelopes characterized from a 4-mm sample volume allowed measurement of peak flow velocity of the early rapid filling wave (E-wave) and peak flow velocity of the late filling wave due to atrial contraction (A-wave). The ratio E/A was calculated. In the same apical view, and using a 2-mm sample volume, tissue Doppler assessment of basal septal, LV lateral wall, as well as RV lateral wall peak early diastolic (E 0 ) and late atrial (A 0 ) myocardial velocities were completed. From apical four-chamber images, we completed post-hoc analysis of longitudinal cardiac deformation analysis in the RV and LV. Myocardial speckle tracking analysis of regional strain (Ɛ) and strain rates (SR: systole, early diastole, and atrial diastole) were determined in basal, mid, and apical wall segments for the septum, LV lateral wall, and RV lateral wall. In all cases, semi-automated wall tracking was applied with frame rates as high as possible (but below 90 fps) and all images were optimized with gain, compression, and dynamic range to enhance myocardial definition.
Statistics
Statistical analysis was performed using SPSS 21.0 (SPSS, Chicago, Illinois, USA) software. All data were reported as mean AE SD and statistical significance was assumed at P ≤ 0.05. Two-way repeated measures ANOVA (time [four levels] -pre vs 0 vs 1 vs 3 h post-exercise, intervention [two levels] -RIPC vs control) was used to assess changes across the TT in our primary and secondary outcome parameters, and whether these changes differ when exercise was preceded by RIPC. When a significant main or interaction effect was observed, post-hoc analysis using Bonferroni testing to correct for multiple comparisons was performed.
Results

Maximal cycling test
The mean VO 2peak was 50.1 AE 7.6 mL.kg/min. Peak HR was 182 AE 9 beats/min and the average peak power attained was 346 AE 63 W. All individuals reported that lower limb local fatigue was responsible for cessation of exercise.
One-hour time trial performance
Both average power output and cycle distance were not different between RIPC and SHAM groups (179 AE 47 W vs 183 AE 53 W, P > 0.05; 31.96 AE 3.08 km vs 32.10 AE 2.47 km, P > 0.05, respectively). No significant changes in body mass or blood pressure were found between or within trials (P > 0.05, respectively). Average HR was not different between RIPC and SHAM (154 AE 16 beats/min vs 151 AE 16 beats/min, P > 0.05). Similarly, there was no difference in average RPE between both RIPC and SHAM conditions (15 AE 2 vs 15 AE 1, respectively, P > 0.05).
Cardiac biomarkers
At rest, hs-cTnT was not different between RIPC and SHAM trials (P > 0.05). Absolute hs-cTnT levels were lower after RIPC than SHAM across all time points post-exercise (main effect for trial: P < 0.05), but there was no main effect of time or time-by-trial interaction (both P > 0.05, Fig. 1a) . Maximal values for hs-cTnT occurred POST-3H (RIPC: 20 AE 9 ng/L vs SHAM: 25 AE 8 ng/L, P = 0.08). No main effect of time, trial, or time-bytrial interaction was observed for NT-proBNP (all P > 0.05, Fig. 1b ).
Cardiac function
There was a main effect of time for HR after exercise (P < 0.001) but no time-by-trial interaction (Table 1 ). There was no main effect of time, trial, or time-by-trial interaction for LVEDV, a surrogate of preload, LVEF or RVFAC (P > 0.05, Table 1;  Table 3 ). A main effect of time was evident for E peak velocity (P < 0.05) with E dropping immediately after exercise in both trials with a recovery by POST-3H. Changes in E contributed to a drop in E/ A immediately post-exercise, but this did not reach statistical significance (P = 0.06). Additionally, there was no change in E/e 0 ratio between conditions (P > 0.05). A main effect of time was also noted for E 0 in the LV (Table 2) , although these changes were small and did not differ between SHAM and RIPC trials. A main effect of time was also observed for LV longitudinal peak systolic strain rate (SSR) with values increasing at POST-1H and POST-3H (P = 0.003 and 0.007, respectively, Table 2 ). A main effect of time was noted for LV longitudinal ASR with increased values at POST-3H (P = 0.006) as well as a main effect of trial with lower values reported throughout the RIPC trial (P = 0.011). No effect of time or trial was observed for peak Ɛ, early diastolic strain rate, or SSR (P > 0.05).
Discussion
The primary aim of this study was to investigate whether RIPC influenced exercise-induced changes in cardiac biomarker release and cardiac function. The key findings from the current study are: (a) there is some evidence that hs-cTnT release following 1-h TT cycling is attenuated when exercise is preceded by RIPC; (b) post-exercise NT-proBNP was not altered by RIPC; and (c) RIPC prior to a 1-h cycling TT did not influence post-exercise cardiac function. The association of lower hs-cTnT levels after RIPC suggests that ischemia may contribute (in part) to exercise-induced elevation in hs-cTnT.
Cardiac biomarkers
Baseline hs-cTnT was slightly higher (>14 ng/L) in the current study compared to previous work. A previous large sample study (n = 545) reported a 99th percentile of 30 ng/L (Collinson et al., 2012 ) which suggests the current data are likely within the "normal" spectrum. A post-exercise elevation in hs-cTnT, a highly specific marker of cardiomyocyte insult, has been observed previously (La Gerche et al., 2008; Duttaroy et al., 2012) . The increase in hs-cTnT values post-exercise in the current study was smaller than those observed in past research (Duttaroy et al., 2012) , which may be partially explained by between-study differences in exercise intensity and/ or exercise duration (Fu et al., 2009) or the higher baseline levels observed compared to previous work. A systematically lower set of hs-cTnT data was observed after exercise in the RIPC compared to the SHAM trial (significant main effect of trial). This provides the first, tentative, suggestion that RIPC can attenuate hs-cTnT release that occurs as a consequence of acute endurance exercise. This contradicts the only previous study that examined the effects of RIPC on exercise-related changes in cTnI, which did not find an effect of RIPC (El Messaoudi et al., 2013) . The difference in outcomes may be explained by a combination of factors, related to the exercise and RIPC stimulus, and also variability in participant training status. El Messaoudi et al. (2013) included relatively untrained subjects, while the intensity of exercise was lower than in the present study. Furthermore, El Messaoudi et al. employed a 3 9 5 min bilateral forearm RIPC protocol occluding a smaller muscle mass for a shorter duration compared to the current study, which may have limited the cardioprotective stimulus.
It is tempting to suggest that the mechanism(s) underpinning the lower hs-cTnT data after exercise in the RIPC trial are consistent with the ischemia/reperfusion-induced cardio-protective adaptation observed in previous animal studies using IPC (Jean-St-Michel et al., 2011). While direct evidence between RIPC and inhibition of mitochondrial permeability transition pore (mPTP) opening is yet to be established (Sharma et al., 2015) , it is apparent that mitochondrial K ATP channel opening does occur. RIPC inhibits mPTP opening upon reperfusion and offers cardio-protection in similar fashion to both the reperfusion injury salvage kinase and survivor activating factor enhancement pathways, which are also activated following RIPC (Heusch et al., 2015; Sharma et al., 2015) . Opening of K ATP channels additionally activates downstream signaling of protein kinase C-e, shown to also offer cardio-protective effects (Wolfrum et al., 2002) . It is suggested both humoral and neural pathways could be responsible for the transmission of cardio-protective signals to the heart following RIPC (Sharma et al., 2015) ; however, the exact contribution of each pathway remains unclear. Therefore, any resultant change from RIPC does not necessarily provide direct evidence for an ischemicmediated mechanism or event.
Sphingosine-1-phosphate (S1P) is a molecule recently demonstrated to reduce ischemia/reperfusion (I/R)-induced cardiac damage (Santos-Gallego et al., 2016) and to mediate the mechanism of RIPCinduced cardio-protection (Jin et al., 2004) . Interestingly, S1P can also be produced in skeletal muscle (Baranowski et al., 2015) , thus intramuscular S1P release in response to RIPC could influence the cardio-protective response following exercise. Additionally, the observation that plasma S1P levels are only elevated by high-intensity exercise (Baranowski et al., 2015) could explain why in previous work (Neilan et al., 2006) , athletes with less training experience (i.e., less S1P release) showed more severe exercise-induced cardiac damage.
While our study may provide the first indirect evidence of the role of ischemia in exercise-induced hs-cTnT elevation, there are some important caveats. Firstly, the elevation in hs-cTnT after exercise in the SHAM trial was small compared to previous studies in different exercise circumstances . Secondly, there was no significant statistical interaction term (time-by-trial) for the hs-cTnT data. Finally, there was no other corroborative evidence of ischemia, such as ECG changes. At this preliminary stage in the evaluation of mechanism(s) underpinning hs-cTnT changes after acute exercise (and the ability of RIPC to prevent such changes), we cannot, categorically, rule out other potential mechanisms.
We did not observe any effect of time, trial, or an interaction of these factors on NT-proBNP. An elevation in NT-proBNP has been positively correlated with exercise duration, with significantly higher serum levels occurring post-ultramarathon (100 km run) when compared to marathon running (Scharhag et al., 2005) . The time (or exercise volume)-dependent increase in NT-proBNP reflects an increased BNP expression in over-stretched myocytes in vitro.
On the basis that no changes in NT-proBNP were reported after both short-endurance and high-intensity exercise (El Messaoudi et al., 2013; Benda et al., 2015) , it is suggested the exercise volume in the current study may have been insufficient to stimulate a significant NT-proBNP response.
Cardiac function
No post-exercise changes in LV systolic function were observed in either trial. This is in line with previous studies employing a relatively short (1 h) endurance exercise exposure (Oxborough et al., 2012) . For example, Palatini et al. (1994) reported no change in LV systolic function following 50-80 min of cycling to exhaustion at anaerobic threshold. It would seem that systolic function is well maintained in the face of this type of acute exercise exposure. Nonetheless, small changes in diastolic function were observed during recovery from exercise in both trials in our study, and as such, changes were not mediated by RIPC. A transient decline in peak E diastolic flow velocity after exercise, with a return to baseline by the POST-3H, has been confirmed in a range of previous studies and this effect is summarized in a meta-analysis (Middleton et al., 2006) . There is evidence to suggest transient declines in diastolic, but not systolic function can occur following shorter duration exercise (<6 h) (Middleton et al., 2006) . A post-exercise, transient decline in diastolic function has been postulated to be due to a decrease in preload, ischemia and damage, and/or other intrinsic processes (Oxborough et al., 2010) . The current study would tend to suggest that ischemia is not a key candidate, due to the consistency of post-exercise changes in these measures of diastolic function in both the RIPC and SHAM trials. Further research is needed, preferably in situations where the heart is exposed to a longer period of exercise.
Implications
Based on our observations and the post-exercise kinetics of cTnT release observed in other work (Middleton et al., 2008) , it is likely the small post-exercise changes in hs-cTnT do not represent long-term irreversible myocardial damage (La Gerche et al., 2008; Shave et al., 2010) . The observation that RIPC may at least partially mediate changes in hs-cTnT appearance after prolonged exercise warrants ongoing study. It is also apparent that post-exercise changes in LV diastolic function are small, transient, and likely to have no performance and/or clinical relevance (Middleton et al., 2006 ). In the current study, there was no association between hs-cTnT and changes in LV diastolic function. The lack of association between changes in cTn and cardiac function after endurance exercise is common and supports the hypothesis that increases in cTn and decreases in LV function represent two different phenomenon that are not causally linked.
Limitations
Individual variability in hs-cTnT response in the current study likely restricted statistical significance on post-hoc analysis. The relatively small sample size used (N = 14) may have also contributed to absence of statistical significance for the post-hoc comparisons. The limited exercise volume and blood sampling protocol employed in the current study may have led to "blunted" hscTnT data. While there is little data assessing cTn kinetics during and after endurance cycling, Middleton et al. (2008) noted that cTnT peaked between 60 and 120 min during treadmill running with a secondary peak between 3 and 12 h postexercise. A more frequent blood sampling protocol (between 3 and 12 h post-exercise) may have further clarified any between-trial differences observed in cTnT based on the trend for increasing post-exercise hs-cTnT levels in SHAM at POST-3H, and subsequently, a progressive increase in the difference between SHAM vs RIPC. It is therefore advisable that future RIPC studies should employ more frequent blood draws and employ a larger exercise stimulus. The use of a 7-day washout between trials ensured participants were in similar physical condition. A longer washout period may be advisable in future studies following new observations of circulating cardioprotective factors 6 days after RIPC treatment in animals (Hildebrandt et al., 2016) . The use of counterbalanced and randomized trial order in the present study should have accounted for any delayed humoral alterations during SHAM condition exercise. All participants were instructed to undertake no exercise 24 h prior to laboratory visits but we cannot confirm if any (intense) exercise performed 24-48 h prior to laboratory testing, influenced baseline hs-cTnT data.
Conclusion
Overall, serum hs-cTnT concentrations were lower in the RIPC vs SHAM condition. While there was a trend for an increasing difference in hs-cTnT between conditions as time progressed, this was not met with a significant main effect for time, or timeby-trial interaction. This provides the first, indirect, evidence that ischemia may be implicated as a mechanism in changes in hs-cTnT post-exercise. RIPC did not mediate post-exercise changes in NT-proBNP, LV systolic function, or LV diastolic function, providing further support to the hypothesis that exercise-induced changes in cTn may not be directly related to changes in cardiac function.
New findings/brief perspective RIPC is associated with reduced myocardial infarct size following ischemic exposures. The effect RIPC can have on both cTnT response and cardiac function following an intense exercise TT bout has not previously been explored.
We show that RIPC is associated with lower cTnT elevation following cycling TT exercise, providing the first, indirect evidence that ischemia may be implicated as a mechanism in changes in cTnT postexercise.
